OPTIMAL DURATION OF DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Clicks: 10
ID: 331314
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #318 of 330 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 330 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Coronary artery disease is commonly managed with percutaneous coronary intervention (PCI) followed by dual antiplatelet therapy (DAPT). However, bleeding risk has driven interest in shorter DAPT durations. This network meta-analysis evaluates the efficacy and safety of different DAPT durations after PCI. Methods PubMed, EuropePMC, and Scopus were searched for randomized controlled trials (RCTs) comparing short-duration (1, 3, or 6 months) versus 12-month DAPT after PCI with drug-eluting stents (DES). Outcomes included net adverse clinical events (NACE), major adverse cardiovascular events (MACE), bleeding, mortality, myocardial infarction, stroke, revascularization, and stent thrombosis. Risk ratios were pooled using random-effects pairwise and network meta-analysis. Results Sixteen RCTs (33,832 patients) were included. One-month (RR 0.58; 95% CI 0.45–0.75; p < 0.0001) and 3-month (RR 0.70; 95% CI 0.58–0.84; p = 0.0002) DAPT followed by P2Y12 inhibitor monotherapy reduced NACE compared with 12-month DAPT. Clinically relevant bleeding was reduced with P2Y12 monotherapy after 1-month (RR 0.40; 95% CI 0.27–0.60; p < 0.0001) and 3-month DAPT (RR 0.62; 95% CI 0.51–0.76; p < 0.0001), with major bleeding lowest at 1 month (RR 0.31; 95% CI 0.20–0.48; p < 0.0001) and reduced at 3 months (RR 0.52; 95% CI 0.37–0.74; p = 0.0002). No significant differences were observed in other outcomes. Ranking favored P2Y12 inhibitor-based strategies, particularly the 1-month regimen. Conclusion Short-duration DAPT followed by P2Y12 inhibitor monotherapy, particularly the 1-month regimen, provides the most favorable balance between reduced bleeding and preserved ischemic protection compared with standard 12-month DAPT after PCI.Figure 1.Forest Plot of Network Meta-Analysis for Clinical Outcomes
Reference Key
openalex_W7220437380 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors P L Artanti, B B Bramantyo, B Hafizhah, N N P Napitupulu, S Nathania
Are you one of these authors? Claim your profile
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag119.038
URL
https://doi.org/10.1093/eurheartjsupp/suag119.038
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.